CEO Sells $2.75 Million in Shares Following Recent Insider Distribution
MLTX has more than doubled off its 52-week low of $5.95.
Summary
MoonLake Immunotherapeutics' CEO, Jorge Santos da Silva, sold 150,000 shares for approximately $2.75 million, executing a previously declared intent to sell and adding to a recent pattern of significant insider sales.
Key Events · Ownership and Investor Activity · MLTX
-
CEO Sells Shares
CEO Jorge Santos da Silva disposed of 150,000 Class A ordinary shares.
-
Transaction Value
The shares were sold for a total value of approximately $2.75 million.
-
Execution of Prior Intent
This sale executes the intent declared in a Form 144 filed by the CEO on April 10, 2026.
-
Part of Broader Insider Selling
This transaction adds to a recent pattern of significant insider sales, including a $63 million sale by a major institutional investor earlier in April.
Analysis · MLTX · Life Sciences
This Form 4 reports the sale of 150,000 shares by MoonLake Immunotherapeutics' CEO, Jorge Santos da Silva, for a total of approximately $2.75 million. This transaction follows a Form 144 filed by the CEO on April 10, 2026, indicating an intent to sell these shares, and represents the execution of that intent. The sale, occurring between April 10 and April 13, is a notable disposition by a key executive. It also contributes to a broader trend of significant insider selling at the company, which has seen over $64 million in net insider sales in the last 90 days, including a substantial $63 million sale by a 10% owner and director affiliate earlier this month. This continued distribution by insiders could be perceived negatively by investors.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLTX was trading at $18.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $5.95 to $62.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.